Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy.
Publication/Presentation Date
6-23-2022
Abstract
Strategies to augment immunity to self/neoantigens expressed by cancers are urgently needed to expand the proportion of patients benefiting from immunotherapy, particularly for GI cancers where only a fraction of patients respond to immunotherapies. However, current vaccine strategies are limited by poor immunogenicity, pre-existing vector-specific immunity, and vaccine-induced vector-specific immunity. Here, we examined a prime-boost strategy using a chimeric adenoviral vector (Ad5.F35) that resists pre-existing immunity followed by recombinant Listeria monocytogenes (Lm) to amplify immunity to the GI cancer antigen GUCY2C. This previously unexplored combination enhanced the quantity, avidity, polyfunctionality, and antitumor efficacy of GUCY2C-specific effector CD8
Volume
7
Issue
1
First Page
61
Last Page
61
ISSN
2059-0105
Published In/Presented At
Flickinger, J. C., Jr, Staudt, R. E., Singh, J., Carlson, R. D., Barton, J. R., Baybutt, T. R., Rappaport, J. A., Zalewski, A., Pattison, A., Waldman, S. A., & Snook, A. E. (2022). Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. NPJ vaccines, 7(1), 61. https://doi.org/10.1038/s41541-022-00483-z
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35739202
Department(s)
Administration and Leadership
Document Type
Article